Pages
(Move to ...)
Home
About me
▼
Thursday, October 27, 2022
Big Pharma Investments in RNA Editing
›
When it comes to new platform technologies, investors generally like to see their belief validated by large pharmaceutical companies. In ad...
2 comments:
Saturday, October 15, 2022
At the Core of Highly Active RNA Editing Oligos
›
Increasing the inherent potency of ADAR guide RNAs (AgRNAs) through chemical and structural means is critical for the success of RNA Editi...
2 comments:
Sunday, October 9, 2022
Landmark Chemical Modification Study Shows RNA Editing Ready for the Clinic
›
At this stage, providing investors and the pharmaceutical industry with a clear line of sight that RNA Editing can be readily translated fro...
Thursday, October 6, 2022
RNA Editing Emerging as a Broadly Applicable Oligonucleotide Therapeutics Modality
›
This feels like RNAi all over again. 20 Years after my life-altering journey in RNAi Therapeutics started, I can’t shake a similar sensation...
7 comments:
Tuesday, February 8, 2022
Reuters Article on Novavax: a Rebuttal
›
[disclosure: I own shares in Novavax] The protein-based vaccine by Novavax is about to become the gold standard covid vaccine: proven to ...
Sunday, July 26, 2020
Strong Presumption Moderna Covid Vaccine Infringes on Arbutus IP
›
News last Thursday that the US Patent Trial and Appeal Board (PTAB) upheld a broad liposomal nanoparticle (LNP)-related patent added an ...
2 comments:
‹
›
Home
View web version